MiCrobiota-gut-brain Axis in Resistant Epilepsy

Launched by NIGUARDA HOSPITAL · May 29, 2025

Keywords

ClinConnect Summary

This clinical trial, called "MiCrobiota-gut-brain Axis in Resistant Epilepsy," is studying the connection between gut bacteria and drug-resistant epilepsy (DRE). Epilepsy is a common condition that can be very challenging, especially when medications do not work. Researchers believe that the bacteria living in our gut may play a role in how our brains function and could impact the effectiveness of treatments for epilepsy. The study aims to see if changes in gut bacteria can help improve outcomes for patients undergoing different therapies, like surgery or vagal nerve stimulation.

To participate in this trial, individuals aged 3 to 50 who have been diagnosed with epilepsy or DRE can join, provided they have the support of a caregiver and are willing to give their consent. However, those with certain gastrointestinal disorders or who have recently taken specific medications or special diets will not be eligible. Participants can expect to contribute to important research that could lead to better treatment options for epilepsy by helping scientists understand the role of gut bacteria in the condition.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 3-50 years old;
• • diagnosis of epilepsy at onset or DRE;
• • ensured participation of the patient or a caregiver;
• • willingness to sign the informed consent.
• Exclusion criteria:
• • diagnosis of organic gastrointestinal disorders (e.g. chronic inflammatory bowel disease);
• • special diets;
• • use of antibiotics, corticoids or probiotics in the previous month.